<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01902836</url>
  </required_header>
  <id_info>
    <org_study_id>IC-11-06</org_study_id>
    <nct_id>NCT01902836</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Dialyzed Leukocytes Extracts to Treat Paediatric Moderate Atopic Dermatitis</brief_title>
  <official_title>Efficacy of Human Dialyzed Leukocytes Extracts in Paediatrics Patients With Moderate Atopic Dermatitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Polytechnic Institute, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Infantil de Mexico Federico Gomez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Oftalmología Fundación Conde de Valenciana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Polytechnic Institute, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with atopic dermatitis treated with conventional treatment plus Dialyzed Leukocyte
      Extracts (DLE-oral Transferon) as adjuvant, have better clinical outcome than patients
      treated only with conventional treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical outcome evaluated by SCORAD</measure>
    <time_frame>Day 14</time_frame>
    <description>To determine clinical outcome by SCORAD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunophenotypical changes induced by adjuvant treatment (DLE) (oral Transferon)</measure>
    <time_frame>28 days</time_frame>
    <description>To evaluate immunophenotypical changes, on peripheral blood mononuclear cells (PBMC) before, at day 14, and end of treatment.
Immunophenotypical changes in this study are defined as changes in CLA and CD103 expression on PBMC; and changes in frequency of CD4+CD25+FOXP3 regulatory T cells, before, at day 14, and at end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Childhood Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Conventional Treatment plus DLE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment plus DLE
Conventional treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend;
Dialyzed Leukocyte Extracts as Adjuvant Treatment: oral DLE (Transferon) (2mg/5mL), then every day for 5 days, and then every 72hrs to complete one month.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatment plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Conventional treatment plus placebo:
oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days, then every 48h for 10 days and suspend; plus oral placebo, every day for 5 days, then every 72hrs to complete one month.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conventional treatment plus DLE</intervention_name>
    <description>Paediatric patients with diagnosis of atopic dermatitis according to Hanifin and Rajka and evaluated with SCORAD as moderate atopic dermatitis were included. Patients were randomized and received in a double blind placebo-controlled treatment:
Group 1: Conventional treatment plus DLE Conventional Treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; plus oral DLE (Transferon) (2mg/5mL), every day for 5 days, then every 72hrs to complete one month</description>
    <arm_group_label>Conventional Treatment plus DLE</arm_group_label>
    <other_name>Transferon</other_name>
    <other_name>Dialyzable Leukocytes Extracts</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conventional treatment plus placebo</intervention_name>
    <description>Group 2: Conventional treatment plus placebo. Conventional treatment: Cetirizine 0.25mg/kg oral, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; and oral placebo, every day for 5 days, then every 72hrs to complete one month.</description>
    <arm_group_label>Conventional treatment plus placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Atopic dermatitis diagnosis by Hanifin and Rajka classification

          -  Dermatitis severity: Moderate, according with SCORAD index.

          -  Patients without treatment of topical steroids or immunosuppressants in the last 3
             weeks.

          -  Patients with &quot;informed consent form&quot; signed by both parents, or advisor.

          -  Patients 7 years old or older whom have signed the assent form

        Exclusion Criteria:

          -  Patient who were treated with topical, or systemic steroids and/or immunosuppressants
             and they cannot discontinue their treatment.

          -  Patients who lived far from the hospital and they could not go to the visits.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mirna Toledo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Infantil de Mexico Federico Gomez</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Infantil de México, Fedérico Gómez</name>
      <address>
        <city>México</city>
        <state>DF</state>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2013</study_first_submitted>
  <study_first_submitted_qc>July 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2013</study_first_posted>
  <last_update_submitted>July 26, 2013</last_update_submitted>
  <last_update_submitted_qc>July 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto de Oftalmología Fundación Conde de Valenciana</investigator_affiliation>
    <investigator_full_name>Maria C Jimenez Martinez</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Dialyzable Leukocyte Extracts</keyword>
  <keyword>Transferon</keyword>
  <keyword>atopic dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Chlorpheniramine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

